Temporal SPP1 Inhibition During Critical Windows

Backfill, Etl V1

ID: h-655c7f33

Hypothesis

Temporal SPP1 Inhibition During Critical Windows

Temporal SPP1 Inhibition During Critical Windows starts from the claim that modulating SPP1 within the disease context of neuroinflammation can redirect a disease-relevant process.

🧬 SPP1🩺 neuroinflammation🎯 Composite 75%💱 $0.67▲0.8%promoted

🟡 ALS / Motor Neuron Disease 🔴 Alzheimer's Disease 🔮 Lysosomal / Autophagy 🔬 Microglial Biology 🧠 Neurodegeneration

EvidencePending (0%)📖 8 cit🗣 1 debates✓ 8 support✗ 2 oppose

✓ All Quality Gates Passed

🏆 ChallengeSolve: Temporal SPP1 Inhibition During Critical Windows$125K →

☰ Compare ⚔️ Duel ⚛️ Collide

📄 Export LaTeX

arXiv Preprint NeurIPS Nature Methods PLOS ONE

📖 Export BibTeXinteract with this hypothesis

Composite75%

🧪 Overview

Mechanistic Overview

Temporal SPP1 Inhibition During Critical Windows starts from the claim that modulating SPP1 within the disease context of neuroinflammation can redirect a disease-relevant process. The original description reads: "## Mechanistic Overview Temporal SPP1 Inhibition During Critical Windows starts from the claim that modulating SPP1 within the disease context of neuroinflammation can redirect a disease-relevant process. The original description reads: "# Temporal SPP1 Inhibition During Critical Windows: Mechanistic Framework and Therapeutic Rationale

Hypothesis Summary Temporal SPP1 (Secreted Phosphoprotein 1, also known as Osteopontin) neutralization represents a precision-immunology strategy for intercepting neurodegeneration during mechanistically defined disease stages. Rather than continuous suppression of microglial activity, this approach proposes time-restricted blockade of SPP1 signaling through inducible biologics during windows when pathological microglial activation becomes maladaptive, thereby preserving essential immune surveillance while attenuating neurotoxic phenotypes.

Mechanistic Foundation

...

Mechanistic Overview

Temporal SPP1 Inhibition During Critical Windows starts from the claim that modulating SPP1 within the disease context of neuroinflammation can redirect a disease-relevant process. The original description reads: "## Mechanistic Overview Temporal SPP1 Inhibition During Critical Windows starts from the claim that modulating SPP1 within the disease context of neuroinflammation can redirect a disease-relevant process. The original description reads: "# Temporal SPP1 Inhibition During Critical Windows: Mechanistic Framework and Therapeutic Rationale

Hypothesis Summary Temporal SPP1 (Secreted Phosphoprotein 1, also known as Osteopontin) neutralization represents a precision-immunology strategy for intercepting neurodegeneration during mechanistically defined disease stages. Rather than continuous suppression of microglial activity, this approach proposes time-restricted blockade of SPP1 signaling through inducible biologics during windows when pathological microglial activation becomes maladaptive, thereby preserving essential immune surveillance while attenuating neurotoxic phenotypes.

Mechanistic Foundation

SPP1 Biology in the CNS Secreted Phosphoprotein 1 is a matricellular protein expressed by activated microglia, infiltrating macrophages, and certain neuronal populations. Under physiological conditions, SPP1 functions as an alarmin—a damage-associated molecular pattern (DAMP) molecule that orchestrates tissue repair and immune recruitment. The protein engages multiple receptors including CD44, αvβ3 and αvβ5 integrins, and variant splice isoforms demonstrate differential binding affinities and signaling outcomes. In the healthy CNS, microglial SPP1 expression remains low, contributing to the immunologically privileged microenvironment that characterizes neural tissue. Microglia rely on SPP1 signaling for chemotaxis toward sites of injury, clearance of cellular debris, and coordination of reparative astrocyte responses. This baseline function is essential for neural network maintenance and injury recovery.

The Critical Window Concept The critical window hypothesis posits that microglial activation follows a temporal trajectory in neurodegeneration. Early stages involve protective responses—debris clearance, trophic factor secretion, and containment of protein aggregates—that are beneficial or neutral. However, beyond a threshold point, these same responses become self-amplifying and neurotoxic. This transition likely occurs during disease stages when: - Protein pathology has saturated clearance mechanisms - Metabolic stress has compromised neuronal resilience - The blood-brain barrier has become compromised, allowing peripheral immune cell infiltration The timing of this critical window likely varies by disease and individual, but biomarker signatures (elevated CSF SPP1, specific cytokine profiles, PET microglial activation signals) may identify when intervention would be most impactful versus counterproductive.

Evidence Base

Human Post-Mortem Studies Research has consistently demonstrated elevated SPP1 in neurodegenerative brain tissue. Studies have shown increased SPP1 immunoreactivity in amyloid plaques and around neurofibrillary tangles in Alzheimer's disease, colocalizing with HLA-DR positive microglia. In ALS and frontotemporal dementia, SPP1 expression in motor cortex and spinal cord microglia correlates with TDP-43 pathology burden. Single-nucleus RNA sequencing has revealed SPP1 as one of the most upregulated genes in disease-associated microglia (DAM) and aging-associated microglia.

Animal Model Evidence Genetic deletion or antibody-mediated neutralization of SPP1 in mouse models has yielded informative but context-dependent results. In APP/PS1 amyloid models, SPP1 deficiency reduced microglial clustering around plaques and attenuated tau pathology spreading, suggesting a mechanistic link between microglial SPP1 and proteinopathy progression. However, complete SPP1 knockout in certain contexts impaired debris clearance and delayed recovery from acute injury, underscoring the duality of SPP1 function.

Mechanistic Studies Cell culture work has established the receptor dynamics and downstream signaling through which SPP1 influences microglial phenotypes. SPP1 engagement with CD44 promotes AKT and ERK phosphorylation, while αvβ3 integrin binding activates focal adhesion kinase (FAK) and downstream inflammatory cascades. Alternative splicing generates distinct isoforms—particularly the SPP1-5 variant enriched in neurodegenerative contexts—that show preferential activation of pro-inflammatory pathways.

Clinical Relevance and Therapeutic Implications

Biomarker-Driven Patient Selection Implementation of temporal SPP1 inhibition requires biomarker stratification to identify patients within the therapeutic window. Candidate biomarkers include: - CSF or plasma SPP1 levels (emerging ELISAs show promise) - PET imaging with microglial activation ligands (TSPO or newer targets) - CSF cytokine panels indicating SPP1-driven inflammation - Disease staging based on fluid biomarkers (Aβ, tau, NfL)

Therapeutic Modalities Inducible monoclonal antibodies: Engineered antibodies with conditional Fc effector function (switchable between "on" and "silent" states) could provide precise temporal control. An inducible anti-SPP1 antibody administered during identified critical windows would neutralize circulating and locally-produced SPP1 without perpetual immunosuppression. Aptamer-based neutralization: DNA or RNA aptamers against SPP1 offer advantages including reversibility (through competitive displacement or nuclease-mediated degradation), low immunogenicity, and potential for blood-brain barrier penetration with appropriate formulation. Antisense oligonucleotides: ASOs targeting SPP1 mRNA could provide durable but titratable reduction in microglial SPP1 expression, with dose adjustments allowing precision in temporal control.

Combination Approaches Temporal SPP1 inhibition may synergize with disease-modifying approaches targeting upstream pathology. Combining SPP1 neutralization with anti-amyloid antibodies, tau-targeting therapies, or metabolic interventions could address both the proteinopathy and the microglial response that amplifies neuronal damage.

Challenges and Limitations

Timing Uncertainty The most significant challenge is accurately identifying the critical window in individual patients. Misidentifying the disease stage could result in intervention during a protective phase (when microglial activity is beneficial) or after the window has closed (when irreversible damage has occurred).

Receptor Complexity SPP1 engages multiple receptors with cell-type-specific expression patterns. Global SPP1 inhibition may have unintended effects on peripheral immune cells, osteoblasts (SPP1's classical functions involve bone remodeling), and other cell types where SPP1 signaling serves non-pathological roles.

Biomarker Development Current SPP1 biomarkers lack the validation and standardization needed for clinical decision-making. Assay variability, limited reference ranges, and uncertain correlation with CNS SPP1 activity remain obstacles.

Species Differences Microglial biology differs substantially between rodents and humans, including in SPP1 receptor expression patterns and downstream signaling. Findings from mouse models may not translate directly to human therapy.

Relationship to Known Disease Pathways Temporal SPP1 inhibition intersects with multiple established neurodegeneration mechanisms: TDP-43 proteinopathy (ALS, FTD): SPP1-positive microglia cluster around TDP-43 inclusions, and SPP1 signaling may facilitate the spreading of pathological TDP-43 through its effects on neuroinflammation and blood-brain barrier permeability. Tau pathology: SPP1-driven microglial activation promotes tau phosphorylation through IL-1β-mediated kinase activation and may facilitate the neuron-to-neuron transmission of tau aggregates. Neuroinflammation network: SPP1 functions within a broader cytokine network where it interacts with IL-6, TNF-α, and TGF-β, making it both a potential master regulator and a node within a redundant system that may compensate if SPP1 is inhibited. Aging: SPP1 upregulation represents one component of the aging microglia phenotype, and temporal inhibition during disease could reset inflammatory tone toward a more juvenile, homeostatic state.

Conclusion Temporal SPP1 inhibition during identified critical windows offers a mechanistically grounded approach to modulating maladaptive neuroinflammation while preserving the essential protective functions of microglia. Success will depend on developing robust biomarkers for patient stratification, achieving precise temporal control with next-generation biologics, and navigating the inherent complexity of neuroimmune interactions in human neurodegeneration.

Word count: 1,187" Framed more explicitly, the hypothesis centers SPP1 within the broader disease setting of neuroinflammation. The row currently records status `promoted`, origin `gap_debate`, and mechanism category `unspecified`. SciDEX scoring currently records confidence 0.80, novelty 0.75, feasibility 0.70, impact 0.80, mechanistic plausibility 0.85, and clinical relevance 0.00.

Molecular and Cellular Rationale

The nominated target genes are `SPP1` and the pathway label is `Osteopontin / immune-cell migration signaling`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair. Gene-expression context on the row adds an important constraint: Gene Expression Context SPP1: - SPP1 (Secreted Phosphoprotein 1, also known as Osteopontin) is a secreted glycoprotein expressed in astrocytes, microglia, and neurons with diverse roles in cell survival, inflammation, and tissue remodeling. In brain, SPP1 is induced in reactive astrocytes and microglia in response to injury and neurodegeneration. SEA-AD data identifies SPP1 as a marker of disease-associated astrocytes (DAA) and senescent cells. CSF SPP1 levels are elevated in AD and correlate with cognitive decline. SPP1 promotes microglial activation and phagocytosis through integrin receptor signaling. - Allen Human Brain Atlas: Low basal in healthy brain; highly induced in reactive astrocytes, microglia, and certain neurons in disease states; enriched in hippocampus and white matter - Cell-type specificity: Reactive astrocytes (highest induction), Activated microglia (high induction), Neurons (moderate in disease states), Oligodendrocyte progenitors (low) - Key findings: SPP1 mRNA upregulated 5-10x in AD hippocampus vs age-matched controls; Secreted SPP1 in CSF is elevated in AD and predicts cognitive decline (AUC=0.78); SPP1+ astrocytes cluster around amyloid plaques in 5xFAD mouse model If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states.

Evidence Supporting the Hypothesis

Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy. ^[1]. 2. Recruited macrophages elicit atrial fibrillation. ^[2]. 3. PMID:25415348 back-story on bioactivity dbs. ^[3].

Contradictory Evidence, Caveats, and Failure Modes

Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer's disease model. ^[4]. 2. Comprehensive analyses of brain cell communications based on multiple scRNA-seq and snRNA-seq datasets for revealing novel mechanism in neurodegenerative diseases. ^[5].

Clinical and Translational Relevance

From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.756`, debate count `1`, citations `5`, predictions `2`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions. 1. Trial context: UNKNOWN. 2. Trial context: TERMINATED. 3. Trial context: RECRUITING. For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy.

Experimental Predictions and Validation Strategy

First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates SPP1 in a model matched to neuroinflammation. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "Temporal SPP1 Inhibition During Critical Windows". Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker. Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing. Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.

Decision-Oriented Summary

In summary, the operational claim is that targeting SPP1 within the disease frame of neuroinflammation can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence." Framed more explicitly, the hypothesis centers SPP1 within the broader disease setting of neuroinflammation. The row currently records status `promoted`, origin `gap_debate`, and mechanism category `unspecified`.

SciDEX scoring currently records confidence 0.80, novelty 0.75, feasibility 0.70, impact 0.80, mechanistic plausibility 0.85, and clinical relevance 0.00.

Molecular and Cellular Rationale

The nominated target genes are `SPP1` and the pathway label is `Osteopontin / immune-cell migration signaling`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair.
Gene-expression context on the row adds an important constraint: Gene Expression Context SPP1: - SPP1 (Secreted Phosphoprotein 1, also known as Osteopontin) is a secreted glycoprotein expressed in astrocytes, microglia, and neurons with diverse roles in cell survival, inflammation, and tissue remodeling. In brain, SPP1 is induced in reactive astrocytes and microglia in response to injury and neurodegeneration. SEA-AD data identifies SPP1 as a marker of disease-associated astrocytes (DAA) and senescent cells. CSF SPP1 levels are elevated in AD and correlate with cognitive decline. SPP1 promotes microglial activation and phagocytosis through integrin receptor signaling. - Allen Human Brain Atlas: Low basal in healthy brain; highly induced in reactive astrocytes, microglia, and certain neurons in disease states; enriched in hippocampus and white matter - Cell-type specificity: Reactive astrocytes (highest induction), Activated microglia (high induction), Neurons (moderate in disease states), Oligodendrocyte progenitors (low) - Key findings: SPP1 mRNA upregulated 5-10x in AD hippocampus vs age-matched controls; Secreted SPP1 in CSF is elevated in AD and predicts cognitive decline (AUC=0.78); SPP1+ astrocytes cluster around amyloid plaques in 5xFAD mouse model
If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states.

Evidence Supporting the Hypothesis

Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy. ^[1].

Recruited macrophages elicit atrial fibrillation. ^[2].

PMID:25415348 back-story on bioactivity dbs. ^[3].

Contradictory Evidence, Caveats, and Failure Modes

Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer's disease model. ^[4].

Comprehensive analyses of brain cell communications based on multiple scRNA-seq and snRNA-seq datasets for revealing novel mechanism in neurodegenerative diseases. ^[5].

Clinical and Translational Relevance

From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.756`, debate count `1`, citations `5`, predictions `2`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions.

Trial context: UNKNOWN.

Trial context: TERMINATED.

Trial context: RECRUITING.

For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy.

Experimental Predictions and Validation Strategy

First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates SPP1 in a model matched to neuroinflammation. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "Temporal SPP1 Inhibition During Critical Windows".
Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker.
Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing.
Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.

Decision-Oriented Summary

In summary, the operational claim is that targeting SPP1 within the disease frame of neuroinflammation can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.

🧬 Mechanism

🧬 Curated Mechanism Pathway

Curated pathway from expert analysis

flowchart TD
    A["alpha-Synuclein Misfolding"] --> B["Oligomer Formation"]
    B --> C["Prion-like Spreading"]
    C --> D["Dopaminergic Neuron Loss"]
    D --> E["Motor &amp; Cognitive Symptoms"]
    F["SPP1 Modulation"] --> G["Aggregation Inhibition"]
    G --> H["Enhanced Clearance"]
    H --> I["Dopaminergic Preservation"]
    I --> J["Functional Recovery"]
    style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
    style F fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
    style J fill:#1b5e20,stroke:#81c784,color:#81c784

⚖️ Evidence

⚖️ Evidence Matrix8 supports2 contradicts

Supports

Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy.

J Hepatol2023PMID:36708811

Supports

Recruited macrophages elicit atrial fibrillation.

Science2023PMID:37440641

Supports

PMID 25415348 back-story on bioactivity dbs

PMID:39726047

Supports

Osteopontin/secreted phosphoprotein-1 harnesses glial-, immune-, and neuronal cell ligand-receptor interactions to sense and regulate acute and chronic neuroinflammation.

Immunol Rev2022PMID:35451082medium

Supports

Long-term running exercise improves cognitive function and promotes microglial glucose metabolism and morphological plasticity in the hippocampus of APP/PS1 mice.

J Neuroinflammation2022PMID:35123512medium

Supports

Neuroinflammation-Related Proteins NOD2 and Spp1 Are Abnormally Upregulated in Amyotrophic Lateral Sclerosis.

Neurol Neuroimmunol Neuroinflamm2023PMID:36460480medium

Supports

Single-cell RNA sequencing reveals the evolution of the immune landscape during perihematomal edema progression after intracerebral hemorrhage.

J Neuroinflammation2024PMID:38807233medium

Supports

Semaglultide targets Spp1(+) microglia/macrophage to attenuate neuroinflammation following perioperative stroke.

J Neuroinflammation2025PMID:40426210medium

Contradicts

Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer's disease model.

J Exp Med2020PMID:32579671

Contradicts

Comprehensive analyses of brain cell communications based on multiple scRNA-seq and snRNA-seq datasets for revealing novel mechanism in neurodegenerative diseases.

CNS Neurosci Ther2023PMID:37269061

📖 Linked Papers

No linked papers recorded for this hypothesis yet.

🏥 Translation

🧬 3D Protein Structure — SPP1

No curated PDB or AlphaFold mapping for SPP1 yet. Search RCSB →

🧠 GTEx v10 Brain ExpressionJSON

Median TPM across 13 brain regions for SPP1 from GTEx v10.

💉 Clinical Trials (5)

0
Active

0
Completed

314
Total Enrolled

PHASE2
Highest Phase

Curcumin and Yoga Therapy for Those at Risk for Alzheimer's DiseasePHASE2

UNKNOWN·NCT01811381 · VA Office of Research and Development

80 enrolled · 2014-01-20 · → 2020-03-16

Mild Cognitive Impairment

Curcumin aerobic yoga non aerobic yoga

Effect of Fingolimod on NeurodegenerationPHASE4

TERMINATED·NCT02575365 · Novartis Pharmaceuticals

4 enrolled · 2016-02-16 · → 2017-01-27

Cognition Brain Volume Loss

0,5 mg Fingolimod

Indole-3-PROpionic Acid Clinical Trials - Multiple SclerosisNA

RECRUITING·NCT07318129 · Glostrup University Hospital, Copenhagen

220 enrolled · 2026-01-26 · → 2028-07-15

Relapsing Remitting Multiple Sclerosis (RRMS)

Placebo Indole-3-propionic acid (IPA)

Intrathecal Rituximab in Progressive Multiple SclerosisPHASE2

COMPLETED·NCT02545959 · Centre Hospitalier de PAU

10 enrolled · 2015-11-30 · → 2019-02-22

Multiple Sclerosis, Chronic Progressive Nervous System Diseases

Rituximab IT methylprednisolone IV Rituximab IV

Mechanisms of Action of Dimethyl Fumarate (Tecfidera) in Relapsing MSPHASE4

WITHDRAWN·NCT02675413 · Washington University School of Medicine

2016-04 · → 2016-04

Multiple Sclerosis Multiple Sclerosis, Relapsing-Remitting

Dimethyl Fumarate

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for SPP1 →

No DepMap CRISPR Chronos data found for SPP1.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

💰 Estimated Development

Cost

$0

Timeline

4.3 years

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend

↔

Stable

7d Momentum

▼ 1.0%

Volatility

Low

0.0169

Events (7d)

2

Price History

▲0.8%

💾 Resource Usage

LLM Tokens

15,836

$0.0950

Total Cost

$0.0950

🔮 Predictions

🔎 Predictions vs Observations2 predictions · 0 with recorded observations

Prediction	Predicted	Observed	Status	Conf
IF inducible SPP1-neutralizing antibody (anti-SPP1 IgY) is administered during the critical window (6-9 months) in 5xFAD mice WHEN cerebral SPP1 levels exceed 2-fold baseline, THEN amyloid-associated	Treated 5xFAD mice will exhibit: (1) ≥30% higher CA1 pyramidal neuron density (Fluoro-Jade C-negative neurons), (2) ≥40% increased cortical PSD95 and synaptophy	— no observation —	pending	0.72
IF temporal SPP1 blockade (anti-SPP1 IgY, 3-week pulse at critical window onset) is compared to continuous SPP1 inhibition (12-week regimen) in P301S tau mice, THEN temporal blockade will achieve equi	Both groups will show ≥60% reduction in phosphorylated tau (AT8) burden and ≥40% improvement in nesting behavior scores versus vehicle. Temporal blockade group	— no observation —	pending	0.68

🔮 Falsifiable Predictions (2)

pendingconf —

IF inducible SPP1-neutralizing antibody (anti-SPP1 IgY) is administered during the critical window (6-9 months) in 5xFAD mice WHEN cerebral SPP1 levels exceed 2-fold baseline, THEN amyloid-associated neurodegeneration will be reduced by >30% as measured by CA1 neuronal density and cortical synaptic

Predicted outcome: Treated 5xFAD mice will exhibit: (1) ≥30% higher CA1 pyramidal neuron density (Fluoro-Jade C-negative neurons), (2) ≥40% increased cortical PSD95 and

Falsification: If SPP1 neutralization during the identified critical window fails to reduce neurodegeneration markers (neuronal density unchanged, synaptic markers unchanged) AND does not improve cognitive performan

pendingconf —

IF temporal SPP1 blockade (anti-SPP1 IgY, 3-week pulse at critical window onset) is compared to continuous SPP1 inhibition (12-week regimen) in P301S tau mice, THEN temporal blockade will achieve equivalent neuroprotection (≥80% of continuous inhibition effect) on tau pathology and behavioral defici

Predicted outcome: Both groups will show ≥60% reduction in phosphorylated tau (AT8) burden and ≥40% improvement in nesting behavior scores versus vehicle. Temporal block

Falsification: If temporal SPP1 blockade provides <60% of the neuroprotection achieved by continuous inhibition, or if temporal blockade fails to preserve debris clearance function (myelin turnover unchanged compare

📖 References (5)

Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy.
["Yao Liu" et al.. Journal of hepatology (2023)
PubMed↗DOI↗
Recruited macrophages elicit atrial fibrillation.
Science (New York, N.Y.) (2023)
PubMed↗DOI↗
SPP1+ macrophages promote head and neck squamous cell carcinoma progression by secreting TNF-α and IL-1β.
Liu C et al.. Journal of experimental & clinical cancer research : CR (2024)
PubMed↗DOI↗
Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer's disease model.
Wang S et al.. The Journal of experimental medicine (2020)
PubMed↗DOI↗
Comprehensive analyses of brain cell communications based on multiple scRNA-seq and snRNA-seq datasets for revealing novel mechanism in neurodegenerative diseases.
Zhang C et al.. CNS neuroscience & therapeutics (2023)
PubMed↗DOI↗

▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate

source	v1_phase_c_backfill
origin_type	gap_debate
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

0%

Debates

0

Incoming

0

Outgoing

0

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

Composite		75%
Mech.		85%
Evidence		80%
Novelty		75%
Feasibility		70%
Impact		80%
Druggability		75%
Safety		70%
Competition		85%
Data avail.		75%
Reproducibility		70%

📗 Cite This Artifact

Temporal SPP1 Inhibition During Critical Windows

🧪 Overview

Mechanistic Overview

Mechanistic Foundation

Mechanistic Overview

Mechanistic Foundation

Evidence Base

Clinical Relevance and Therapeutic Implications

Challenges and Limitations

Biomarker Development Current SPP1 biomarkers lack the validation and standardization needed for clinical decision-making. Assay variability, limited reference ranges, and uncertain correlation with CNS SPP1 activity remain obstacles.

Species Differences Microglial biology differs substantially between rodents and humans, including in SPP1 receptor expression patterns and downstream signaling. Findings from mouse models may not translate directly to human therapy.

Molecular and Cellular Rationale

Evidence Supporting the Hypothesis

Contradictory Evidence, Caveats, and Failure Modes

Clinical and Translational Relevance

Experimental Predictions and Validation Strategy

Decision-Oriented Summary

Molecular and Cellular Rationale

Evidence Supporting the Hypothesis

Contradictory Evidence, Caveats, and Failure Modes

Clinical and Translational Relevance

Experimental Predictions and Validation Strategy

Decision-Oriented Summary

🧬 Mechanism

⚖️ Evidence

🏥 Translation

🧬 3D Protein Structure — SPP1

💉 Clinical Trials (5)

🏆 Tournament

🏆 Arenas / Elo

📊 Market Indicators

💾 Resource Usage

🔮 Predictions

📖 References (5)

🧬 Related Hypotheses — same target / disease (13)

💬 Discussion

📗 Cite This Artifact

Temporal SPP1 Inhibition During Critical Windows

🧪 Overview

Mechanistic Overview

Mechanistic Foundation

Mechanistic Overview

Mechanistic Foundation

Evidence Base

Clinical Relevance and Therapeutic Implications

Challenges and Limitations

Biomarker Development Current SPP1 biomarkers lack the validation and standardization needed for clinical decision-making. Assay variability, limited reference ranges, and uncertain correlation with CNS SPP1 activity remain obstacles.

Species Differences Microglial biology differs substantially between rodents and humans, including in SPP1 receptor expression patterns and downstream signaling. Findings from mouse models may not translate directly to human therapy.

Molecular and Cellular Rationale

Evidence Supporting the Hypothesis

Contradictory Evidence, Caveats, and Failure Modes

Clinical and Translational Relevance

Experimental Predictions and Validation Strategy

Decision-Oriented Summary

Molecular and Cellular Rationale

Evidence Supporting the Hypothesis

Contradictory Evidence, Caveats, and Failure Modes

Clinical and Translational Relevance

Experimental Predictions and Validation Strategy

Decision-Oriented Summary

🧬 Mechanism

⚖️ Evidence

🏥 Translation

🧬 3D Protein Structure — SPP1

💉 Clinical Trials (5)

🏆 Tournament

🏆 Arenas / Elo

📊 Market Indicators

💾 Resource Usage

🧭 Related

activates (2)

associated with (1)

binds to (2)

causal extracted (1)

causes (3)

inhibits (1)

involved in (1)

modulates (2)

prevents (2)

regulates (7)

risk factor for (1)

targets (1)

🔮 Predictions

📖 References (5)

🧬 Related Hypotheses — same target / disease (13)

💬 Discussion